Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma

被引:0
作者
Patrick B. Johnston
Lauren C. Pinter-Brown
Ghulam Warsi
Kristen White
Radhakrishnan Ramchandren
机构
[1] Mayo Clinic,Division of Hematology
[2] David Geffen School of Medicine at UCLA,Department of Hematology/Oncology
[3] Novartis Pharmaceuticals Corporation,Department of Oncology
[4] Karmanos Cancer Institute,Department of Hematology/Oncology
来源
Experimental Hematology & Oncology | / 7卷
关键词
Clinical trial; Everolimus; Hodgkin lymphoma; mTOR inhibitors; Relapsed/refractory;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 145 条
[1]  
Kuruvilla J(2011)How I treat relapsed and refractory Hodgkin lymphoma Blood 117 4208-4217
[2]  
Keating A(2011)Hodgkin’s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 22 vi55-vi58
[3]  
Crump M(2012)Advances in the treatment of relapsed or refractory Hodgkin’s lymphoma Oncologist 17 367-376
[4]  
Eichenauer DA(1993)Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial Lancet 341 1051-1054
[5]  
Engert A(2002)Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial Lancet 359 2065-2071
[6]  
Dreyling M(2003)Autologous stem cell transplantation for Hodgkin’s disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen Bone Marrow Transplant 32 279-285
[7]  
Ramchandren R(2012)Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation Korean J Hematol 47 8-16
[8]  
Linch DC(2003)Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed Hodgkin’s disease following autologous stem cell transplantation Arch Med Res 34 242-245
[9]  
Winfield D(2010)Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas N Engl J Med 363 1812-1821
[10]  
Goldstone AH(2012)Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma J Clin Oncol 30 2183-2189